Arachidonic acid-induced gene expression in colon cancer cells

Carcinogenesis

Volumn 27, Issue 10, 2006, Pages 1950-1960

  Monjazeb, Arta M ^a   High, Kevin P ^a   Connoy, Abbie ^a   Hart, Lori S ^a   Koumenis, Constantinos ^a   Chilton, Floyd H ^a  

^a WAKE FOREST BAPTIST HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; CASPASE 3; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN C JUN; RAS PROTEIN; SULINDAC SULFIDE; TRANSCRIPTION FACTOR AP 1;

APOPTOSIS; ARACHIDONIC ACID METABOLISM; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CANCER SURVIVAL; CELL PROLIFERATION; CELL STRAIN HCT116; COLON CANCER; COLON CARCINOGENESIS; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; ENZYME ACTIVITY; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION;

APOPTOSIS; ARACHIDONIC ACID; CELL SURVIVAL; COLONIC NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; PROTO-ONCOGENE PROTEINS C-JUN; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION, GENETIC; TRIAZENES;

EID: 33749582769     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgl023     Document Type: Article

References (70)

1. Lands,W.E. (2000) Stories about acyl chains. Biochim. Biophys. Acta, 1483, 1-14.
2. Chilton,F.H., Fonteh,A.N., Surette,M.E., Triggiani,M. and Winkler,J.D. (1996) Control of arachidonate levels within inflammatory cells. Biochim. Biophys. Acta, 1299, 1-15.
3. Chilton,F.H., Surette,M.E. and Winkler,J.D. (1996) Arachidonate-phospholipid remodeling and cell proliferation. Adv. Exp. Med. Biol., 416, 169-172.
4. Monjazeb,A.M., Clay,C.E., High,K.P. and Chilton,F.H. (2002) Antineoplastic properties of arachidonic acid and its metabolites. Prostaglandins Leukot. Essent. Fatty Acids, 66, 5-12.
5. Surette,M.E., Winkler,J.D., Fonteh,A.N. and Chilton,F.H. (1996) Relationship between arachidonate-phospholipid remodeling and apoptosis. Biochemistry, 35, 9187-9196.
6. Cao,Y. and Prescott,S.M. (2002) Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J. Cell Physiol., 190, 279-286.
7. Kokawa,A., Kondo,H., Gotoda,T., Ono,H., Saito,D., Nakadaira,S., Kosuge,T. and Yoshida,S. (2001) Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer, 91, 333-338.
8. Komhoff,M., Guan,Y., Shappell,H.W., Davis,L., Jack,G., Shyr,Y., Koch,M.O., Shappell,S.B. and Breyer,M.D. (2000) Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas. Am. J. Pathol., 157, 29-35.
9. Kulkarni,S., Rader,J.S., Zhang,F., Liapis,H., Koki,A.T., Masferrer,J.L., Subbaramaiah,K. and Dannenberg,A.J. (2001) Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin. Cancer Res., 7, 429-434.
10. Lim,H.Y., Joo,H.J., Choi,J.H., Yi,J.W., Yang,M.S., Cho,D.Y., Kim,H.S., Nam,D.K., Lee,K.B. and Kim,H.C. (2000) Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clin. Cancer Res., 6, 519-525.
11. Sano,H., Kawahito,Y., Wilder,R.L., Hashiramoto,A., Mukai,S., Asai,K., Kimura,S., Kato,H., Kondo,M. and Hla,T. (1995) Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res., 55, 3785-3789.
12. Soslow,R.A., Dannenberg,A.J., Rush,D., Woerner,B.M., Khan,K.N., Masferrer,J. and Koki,A.T. (2000) COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer, 89, 2637-2645.
13. Attiga,F.A., Fernandez,P.M., Weeraratna,A.T., Manyak,M.J. and Patierno,S.R. (2000) Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res., 60, 4629-4637.
14. Dempke,W., Rie,C., Grothey,A. and Schmoll,H.J. (2001) Cyclooxygenase-2: a novel target for cancer chemotherapy? J. Cancer Res. Clin. Oncol, 127, 411-417.
15. Marks,F., Muller-Decker,K. and Furstenberger,G. (2000) A causal relationship between unscheduled eicosanoid signaling and tumor development: Cancer chemoprevention by inhibitors of arachidonic acid metabolism. Toxicology, 153, 11-26.
16. Sheng,H., Shao,J., Morrow,J.D., Beauchamp,R.D. and DuBois,R.N. (1998) Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res., 58, 362-366.
17. Bus,P.J., Verspaget,H.W., Lamers,C.B. and Griffioen,G. (2000) Chemoprevention of colorectal cancer by non-steroidal antiinflammatory drugs. Scand. J. Gastroenterol. Suppl., 232, 101-104.
18. DuBois,R.N., Giardiello,F.M. and Smalley,W.E. (1996) Nonsteroidal antiinflammatory drugs, eicosanoids, and colorectal cancer prevention. Gastroenterol. Clin. North Am., 25, 773-791.
19. Giovannucci,E. (1999) The prevention of colorectal cancer by aspirin use. Biomed. Pharmacother., 53, 303-308.
20. Watson,A.J. (1998) Chemopreventive effects of NSAIDs against colorectal cancer: Regulation of apoptosis and mitosis by COX-1 and COX-2. Histol. Histopathol., 13, 591-597.
21. Gao,X., Grignon,D.J., Chbihi,T. et al. (1995) Elevated 12-lipoxygenase mRNA expression correlates with advanced stage and poor differentiation of human prostate cancer. Urology, 46, 227-237.
22. Cao,Y., Dave,K.B., Doan,T.P. and Prescott,S.M. (2001) Fatty Acid CoA Ligase 4 is up-regulated in colon adenocarcinoma. Cancer Res., 61, 8429-8434.
23. Wong,B.C., Wang,W.P., Cho,C.H., Fan,X.M., Lin,M.C., Kung,H.F. and Lam,S.K. (2001) 12-Lipoxygenase inhibition induced apoptosis in human gastric cancer cells. Carcinogenesis, 22, 1349-1354.
24. Cao,Y., Pearman,A.T., Zimmerman,G.A., McIntyre,T.M. and Prescott,S.M. (2000) Intracellular unesterified arachidonic acid signals apoptosis. Proc. Natl Acad. Sci. USA, 97, 11280-11285.
25. Winkler,J.D., Eris,T., Sung,C.M., Chabot-Fletcher,M., Mayer,R.J., Surette,M.E. and Chilton,F.H. (1996) Inhibitors of coenzyme A-independent transacylase induce apoptosis in human HL-60 cells. J. Pharmacol. Exp. Ther., 279, 956-966.
26. Kashfi,K. and Rigas,B. (2005) Non-COX-2 targets and cancer: Expanding the molecular target repertoire of chemoprevention. Biochem. Pharmacol. 969-986.
27. Chan,T.A., Morin,P.J., Vogelstein,B. and Kinzler,K.W. (1998) Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc. Natl Acad. Sci. USA, 70, 681-686.
28. Trimboli,A.J., Waite,B.M., Atsumi,G., Fonteh,A.N., Namen,A.M., Clay,C.E., Kute,T.E., High,K.P., Willingham,M.C. and Chilton,F.H. (1999) Influence of coenzyme A-independent transacylase and cyclooxygenase inhibitors on the proliferation of breast cancer cells. Cancer Res., 59, 6171-6177.
29. Gupta,S., Srivastava,M., Ahmad,N., Sakamoto,K., Bostwick,D.G. and Mukhtar,H. (2001) Lipoxygenase-5 is overexpressed in prostate adenocarcinoma. Cancer, 91, 737-743.
30. Dong,M., Johnson,M., Rezaie,A. et al. (2005) Cytoplasmic phospholipase A2 levels correlate with apoptosis in human colon tumorigenesis. Clin. Cancer Res., 11, 2265-2271.
31. Monjazeb,A.M., High,K.P., Koumenis,C. and Chilton,F.H. (2005) Inhibitors of arachidonic acid metabolism act synergistically to signal apoptosis in neoplastic cells. Prostaglandins Leukot. Essent. Fatty Acids, 73, 463-474.
32. Jurivich,D.A., Sistonen,L., Sarge,K.D. and Morimoto,R.I. (1994) Arachidonate is a potent modulator of human heat shock gene transcription. Proc. Natl Acad. Sci. USA, 91, 2280-2284.
33. Morimoto,R.I., Kroeger,P.E. and Cotto,J.J. (1996) The transcriptional regulation of heat shock genes: A plethora of heat shock factors and regulatory conditions. EXS, 77, 139-163.
34. Razanamahefa,L., Prouff,S. and Bardon,S. (2000) Stimulatory effect of arachidonic acid on T-47D human breast cancer cell growth is associated with enhancement of cyclin D1 mRNA expression. Nutr. Cancer, 38, 274-280.
35. Bordin,L., Priante,G., Musacchio,E., Giunco,S., Tibaldi,E., Clari,G. and Baggio,B. (2003) Arachidonic acid-induced IL-6 expression is mediated by PKC alpha activation in osteoblastic cells. Biochemistry, 42, 4485-4491.
36. Vallve,J.C., Uliaque,K., Girona,J., Cabre,A., Ribalta,J., Heras,M. and Masana,L. (2002) Unsaturated fatty acids and their oxidation products stimulate CD36 gene expression in human macrophages. Atherosclerosis, 164, 45-56.
37. Wang,X.J., Dyson,M.T., Mondillo,C., Patrignani,Z., Pignataro,O. and Stocco,D.M. (2002) Interaction between arachidonic acid and cAMP signaling pathways enhances steroidogenesis and StAR gene expression in MA-10 Leydig tumor cells. Mol. Cell. Endocrinol., 188, 55-63.
38. Bernard-Gallon,D.J., Vissac-Sabatier,C., Antoine-Vincent,D., Rio,P.G., Maurizis,J.C., Fustier,P. and Bignon,Y.J. (2002) Differential effects of n-3 and n-6 polyunsaturated fatty acids on BRCA1 and BRCA2 gene expression in breast cell lines. Br. J. Nutr., 87, 281-289.
39. Hughes-Fulford,M., Chen,Y. and Tjandrawinata,R.R. (2001) Fatty acid regulates gene expression and growth of human prostate cancer PC-3 cells. Carcinogenesis, 22, 701-707.
40. Rizzo,M.T., Boswell,H.S., Mangoni,L., Carlo-Stella,C. and Rizzoli,V. (1995) Arachidonic acid induces c-jun gene expression in stromal cells stimulated by interleukin-1 and tumor necrosis factor-alpha: Evidence for a tyrosine-kinase-dependent process. Blood, 86, 2967-2975.
41. Chilton,F.H., Fonteh,A.N., Sung,C.M., Hickey,D.M., Torphy,T.J., Mayer,R.J., Marshall,L.A., Heravi,J.D. and Winkler,J.D. (1995) Inhibitors of CoA-independent transacylase block the movement of arachidonate into 1-ether-linked phospholipids of human neutrophils. Biochemistry, 34, 5403-5410.
42. Bligh,E.G. and Dyer,W.J. (1959) A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol., 37, 911-920.
43. Huang,F.M., Chou,M.Y. and Chang,Y.C. (2003) Dentin bonding agents induce c-fos and c-jun protooncogenes expression in human gingival fibroblasts. Biomaterials, 24, 157-163.
44. Surette,M.E., Fonteh,A.N., Bernatchez,C. and Chilton,F.H. (1999) Perturbations in the control of cellular arachidonic acid levels block cell growth and induce apoptosis in HL-60 cells. Carcinogenesis, 20, 757-763.
45. Levkovitz,Y. and Baraban,J.M. (2001) A dominant negative inhibitor of the Egr family of transcription regulatory factors suppresses cerebellar granule cell apoptosis by blocking c-Jun activation. J. Neurosci., 21, 5893-5901.
46. Levkovitz,Y. and Baraban,J.M. (2002) A dominant negative Egr inhibitor blocks nerve growth factor-induced neurite outgrowth by suppressing c-Jun activation: Role of an Egr/c-Jun complex. J. Neurosci., 22, 3845-3854.
47. Thun,M.J., Namboodiri,M.M. and Heath,C.W. Jr (1991) Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med., 325, 1593-1596.
48. Barham,J.B., Edens,M.B., Fonteh,A.N., Johnson,M.M., Easter,L. and Chilton,F.H. (2000) Addition of eicosapentaenoic acid to gammalinolenic acid-supplemented diets prevents serum arachidonic acid accumulation in humans. J. Nutr., 130, 1925-1931.
49. Fonteh,A.N., LaPorte,T., Swan,D. and McAlexander,M.A. (2001) A decrease in remodeling accounts for the accumulation of arachidonic acid in murine mast cells undergoing apoptosis. J. Biol. Chem., 276, 1439-1449.
50. Sellmayer,A., Danesch,U. and Weber,P.C. (1997) Modulation of the expression of early genes by polyunsaturated fatty acids. Prostaglandins Leukot. Essent. Fatty Acids, 57, 353-357.
51. Wilker,E and Yaffe,M.B. (2004) 14-3-3 Proteins - a focus on cancer and human disease. J. Mol. Cell Cardiol., 37, 633-642.
52. Kuiperij,H.B., de Rooij,J., Rehmann,H., van Triest,M., Wittinghofer,A., Bos,J.L. and Zwartkruis,F.J. (2003) Characterisation of PDZ-GEFs, a family of guanine nucleotide exchange factors specific for Rap1 and Rap2. Biochim. Biophys. Acta, 1593, 141-149.
53. Zwartkruis,F.J. and Bos,J.L. (1999) Ras and Rap1: Two highly related small GTPases with distinct function. Exp. Cell Res., 253, 157-165.
54. Leffers,H., Nielsen,M.S., Andersen,A.H., Honore,B., Madsen,P., Vandekerckhove,J. and Celis,J.E. (1993) Identification of two human Rho GDP dissociation inhibitor proteins whose overexpression leads to disruption of the actin cytoskeleton. Exp. Cell Res., 209, 165-174.
55. 1-phase cell-cycle regulation. Nat. Rev. Mol. Cell Biol., 5, 355-366.
56. Park,I., Chung,J., Walsh,C.T., Yun,Y., Strominger,J.L. and Shin,J. (1995) Phosphotyrosine-independent binding of a 62-kDa protein to the src homology 2 (SH2) domain of p56lck and its regulation by phosphorylation of Ser-59 in the lck unique N-terminal region. Proc. Natl Acad. Sci. USA, 92, 12338-12342.
57. Angel,P. and Karin,M. (1991) The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim. Biophys. Acta, 1072, 129-157.
58. Shaulian,E. and Karin,M. (2002) AP-1 as a regulator of cell life and death. Nat. Cell Biol., 4, E131-E136.
59. Rizzo,M.T., Leaver,A.H., Yu,W.M. and Kovacs,R.J. (1999) Arachidonic acid induces mobilization of calcium stores and c-jun gene expression: evidence that intracellular calcium release is associated with c-jun activation. Prostaglandins Leukot. Essent. Fatty Acids, 60, 187-198.
60. Liu,Q., Chan,S.T. and Mahendran,R. (2003) Nitric oxide induces cyclooxygenase expression and inhibits cell growth in colon cancer cell lines. Carcinogenesis, 24, 637-642.
61. Meade,E.A., Smith,W.L. and DeWitt,D.L. (1993) Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem., 268, 6610-6614.
62. Jaboin,J., Kim,C.J., Kaplan,D.R. and Thiele,C.J. (2002) Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3′-kinase pathway. Cancer Res., 62, 6756-6763.
63. Matsumoto,K., Wada,R.K., Yamashiro,J.M., Kaplan,D.R. and Thiele,C.J. (1995) Expression of brain-derived neurotrophic factor and p145TrkB affects survival, differentiation, and invasiveness of human neuroblastoma cells. Cancer Res., 55, 1798-1806.
64. Scala,S., Wosikowski,K., Giannakakou,P., Valle,P., Biedler,J.L., Spengler,B.A., Lucarelli,E., Bates,S.E. and Thiele,C.J. (1996) Brainderived neurotrophic factor protects neuroblastoma cells from vinblastine toxicity. Cancer Res., 56, 3737-3742.
65. Cappellen,D., De Oliveira,C., Ricol,D., de Medina,S., Bourdin,J., Sastre-Garau,X., Chopin,D., Thiery,J.P. and Radvanyi,F. (1999) Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat. Genet., 23, 18-20.
66. Li,Z., Zhu,Y.X., Plowright,E.E., Bergsagel,P.L., Chesi,M., Patterson,B., Hawley,T.S., Hawley,R.G. and Stewart,A.K. (2001) The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells. Blood, 97, 2413-2419.
67. Pollett,J.B., Trudel,S., Stern,D., Li,Z.H. and Stewart,A.K. (2002) Overexpression of the myeloma-associated oncogene fibroblast growth factor receptor 3 confers dexamethasone resistance. Blood, 100, 3819-3821.
68. Sibley,K., Stern,P. and Knowles,M.A. (2001) Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours. Oncogene, 20, 4416-4418.
69. Bloom,J. and Pagano,M. (2003) Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin. Cancer Biol., 13, 41-47.
70. Jarvinen,T.A. and Liu,E.T. (2003) Topoisomerase IIalpha gene (TOP2A) amplification and deletion in cancer - more common than anticipated. Cytopathology, 14, 309-313.